Purchase Description 21_005412RFQ.pdf

Version 11-30-2016-1 FAR Part 11—Describing Agency Needs

PURCHASE DESCRIPTION

1. Statement of Need and Purpose:

NCATS ETB is looking to expand its pre-clinical screening library of small molecules. Adding diversity to chemical libraries is imperative to our operation, as we screen a variety of targets against these in-house collections.

2. Background Information and Objective:

Screening is often the starting point in our development and a wealth of knowledge is obtained from screening a diverse collection. It provides the starting point of all information for medicinal chemistry’s structure-activity relationship (SAR) design to synthesize novel compounds that have more desirable properties. A diverse and novel screening collection provides the backbone of our operation and is imperative for translational sciences to obtain effective small molecules with on-target effects.

These small molecules have been designed around analysis of available chemical and biological information, identification of key pathways modules/targets, computational and “wet biology” assessment of target druggability and potential binding domains. The resulting information is analyzed by synthetic and medicinal chemistry teams to bring new chemical diversity and to design unique scaffolds that are likely to interact with the designated targets yielding focused compound libraries. Having such small molecules will make a huge impact in our screening against the variety of targets that NCATS works on and will also help tremendously in bioinformatics analysis which will allow a more thorough and effective SAR expansion by the medicinal chemist.

3. Generic Name of Product: Chemical Library.

4. Purchase Description:

Immediate Delivery

CAT No CAS Product Name

Solution

HY-136 299 103926-64-3 Sepimostat

HY-109035 942123-43-5 lnarigivir soproxil

HY-106859 103337-74-2 Letrazuril

HY-112161 1912445-55-6 Branebrutinib

HY-103095 1001404-83-6 AAl101

HY-112424 1464151-33-4 ETC-206

HY-18729A 51298-62-5 L-NAME (hydrochloride)

HY-16200 180300-43-0 Ethynylcytidine

HY-101755 960151-65-9 Tedatioxetine {hydrobromide}

HY-103248 606-58-6 Toyocamycin

HY-16757 853400-76-7 Trofinetide

HY-119824 22089-22-1 Trofosfamide

HY-106662 97919-22-7 Chloroquinoxaline sulfonamide

HY-18056 857290-04-1 PF-915275

HY-13563 195533-53-0 Batabulin

HY-13648 15866-90-7 lncyclinide

HY-119307 287405-51-0 Apratastat

HY-100401 189198-30-9 Pactimibe

HY-13579 1161233-85-7 BTZ043

HY-13579A 957217-65-1 BTZ043 (Racemate)

HY-N0190 29883-15-6 Amygdalin

HY-103184 1398046-21-3 Proxalutamide

HY-16997A 1334302-63-4 ltacitinib adipate

HY-19900 1252679-52-9 ITX5061

HY-N0043 52705-93-8 Ginsenoside Rd

HY-109187A posenacaftor 2095064-06-3

Solid form

HY-109058 648927-86-0 Firibastat

HY-16772 1213269-98-7 Vatiquinone

HY-17576 129580-63-8 Satraplatin

HY-10443 690270-29-2 Balapiravir

HY-105129 70132-51-3 Pimonidazole hydrochloride

HY-101634 1132936-00-5 abt-072

HY-14824 799279-80-4 sofinicline

HY-101574 153804-05-8 pratosartan

HY-U00076 862309-06-6 mk-0249

HY-U00373 219984-49-3 revexepride

HY-108034 202402-01-5 get-73

HY-14126 187735-94-0 bio-1211

HY-10545A 40372-00-7 taribavirin hydrochloride

HY-101708 97627-24-2 ci-953

HY-121212 1253909-57-7 icosabutate

HY-114080 114568-26-2 patamostat

HY-U00155 56605-16-4 spirornustine

HY-U00208 111786-07-3 prinoxodan

HY-101820 944258-89-3 sim-6802

HY-14934 501948-05-6 rosabulin

HY-109120 501692-44-0 odevixibat

HY-101647 125974-72-3 intoplicine

HY-119810 357336-74-4 seletracetam

HY-16776 634907-30-5 censavudine

HY-19660 155415-08-0 inogatran

HY-19675 385800-16-8 naproxen etemesil

HY-109004 1323077-89-9 enzaplatovir

HY-106014 130306-02-4 tezacitabine

HY-13742 93265-81-7 ropidoxuridine

HY-101630 120444-71-5 deramciclane

HY-16748 1026134-63-3 abt-126

HY-100152 86434-57-3 beperidium

HY-101693 98326-32-0 senazodan

HY-100125 71079-19-1 timegadine

HY-10399 209394-27-4 ladostigil

HY-101705 105102-18-9 tibenelast

HY-106025 219846-31-8 radequinil

HY-15491 837364-57-5 ag-24322

HY-U00232 116078-65-0 bidisornide

HY-19223 158364-59-1 pumaprazole

HY-106405 274925-86-9 nebicapone

HY-111021 952565-91-2 asp-4058

HY-U00186 189362-06-9 k-134

HY-118557 58754-46-4 iferanserin

HY-15072 210245-80-0 zonampanel anhydrous

HY-U00027 101193-62-8 quinotolast

HY-U00398 130493-03-7 bimoclornol

HY-U00031 187219-99-4 axornadol

HY-104029 1928707-56-5 olorofim

HY-108060 640281-90-9 valopicitabinedihydrochloride

HY-U00229 34633-34-6 bifluranol

HY-109079 1902954-60-2 abeprazan

HY-106410 219680-11-2 zabofloxacin

HY-16758 1414854-42-4 verosudil

HY-16138 936221-33-9 ivaltinostat

HY-118561 78499-27-1 bermoprofen

HY-109032 1371591-51-3 firuglipel

HY-13556A 182133-27-3 arzoxifene hydrochloride

HY-16721 632325-71-4 filociclovir

HY-10309 172927-65-0 sibrafiban

HY-N6674 733035-26-2 diazepinomicin

HY-16718 1044535-52-5 dagrocorat

HY-106993 213027-19-1 cipralisant

HY-19864 910562-18-4 aganepag

5. Salient characteristics:

• Small molecules must have validated biological and pharmacological activities.

• Must be available for high-throughput screening (HTS) and high-content screening

(HCS).

• Must come with detailed biological and chemical information with LC/MS and NMR reports to ensure high quality.

• Each small molecule must be guaranteed to have a purity of >95% (accuracy +/-5%) that is to be confirmed by NMR and/or LCMS spectra.

• In addition to the molecules themselves, the Contractor must be able to provide the following electronic information for each required molecule: chemical structure or simplified molecular-input line-entry system (SMILES) or equivalent chemical structure information, supplier ID, plate ID, well location, tube ID, concentration in millimolar, and volume in microliters. This information shall be provided via email referencing individual compound vial barcodes.

6. Quantity:

• One (1) Chemical library of 59 compounds provided in solid format

• One (1) Sepimostat, CAS 103926-64-3, 10mM solution, 0.8mL

• One (1) Chemical library of 25 compounds provided in 10mM solution, 0.8mL each

• One (1) Chemical library of 5 compounds provided in 5mg solid, 5mg each

7. Delivery Date: One-time delivery to be made within 1-10 weeks after receipt of order.

8. Period of Performance: N/A

9. Option(s): N/A